San Diego, CA, November 24, 2013 --(PR.com
)-- Mahmoud Loughman-Adham, Global Medical Director of Baxter BioScience will give a presentation on “The Use of Biomarkers to Accelerate Clinical Development of Drugs for Kidney Diseases” at the 3rd Inflammatory & Immunological Biomarkers Conference on March 19-21, 2014 in San Diego, CA
Dr. Loughman-Adham’s presentation will explain how research into the mechanisms of kidney injury and disease have begun to identify potential drug targets, but the pace of new drug development in kidney diseases remains very slow. Identification and validation of new biomarkers of kidney injury should accelerate both preclinical and clinical development of drugs in this important area. Efforts by academia, industry and regulatory agencies have begun to bear fruit by identifying biomarkers that can be used to predict renal injury, progression of chronic kidney disease and cardiovascular complications. Furthermore, inclusion of biomarkers in clinical trials to identify patients more likely to progress, is likely to accelerate development by allowing early go/no go decisions and increasing the probability of success.
Mahmoud Loghman-Adham, MD is a Medical Director at Baxter BioScience in Westlake Village, California. In addition to his role in managing clinical trials, he provides medical and scientific advice to the Business Development group, including evaluation of molecules for in-licensing; he has participated in a number of due diligence activities. Prior to joining Baxter in 2012, he was a Senior Medical Director and a Translational Medicine Leader at Hoffmann-La Roche Inc, starting in 2001. He led clinical trials in renal disease and anemia, including pediatric trials. In his role as translational medicine leader, he provided medical input on the development of multiple drugs for metabolic, renal, and cardiovascular diseases from lead optimization and candidate selection through phase 2. He has worked on biomarker identification and selection and their incorporation into proof-of-concept clinical trials. His areas of interest include chronic kidney disease, nephrotoxicity, and inflammatory/auto-immune diseases.
The 3rd Inflammatory & Immunological Biomarkers Conference brings together experts from industry and academia to discuss the unmet medical needs in autoimmune diseases, respiratory diseases, kidney disease, lupus, IBD and other inflammatory diseases. This conference is part of the larger Biomarker Summit 2014 which includes the following co-located conferences:
1) 7th Oncology Biomarkers
2) 3rd Neurological Biomarkers
For more information, please visit www.gtcbio.com/biomarkers/inflamm